Phase 2 Interstitial Lung Disease Trial, Recruiting NCT01280994 Sponsor: Bastiaan Driehuys Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Phase 2 Interstitial Lung Disease Trial, Recruiting

NCT01280994
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you are a healthy volunteer:

  • You have no diagnosed lung conditions
  • You have not smoked in the past 5 years
  • If you have smoked in the past, your total smoking history is 5 pack-years or less (roughly 5 years of smoking one pack per day, or equivalent)

If you have a lung condition:

  • A doctor has diagnosed you with a lung or breathing condition
  • Your lung condition has not gotten suddenly worse in the past 30 days

Who may not be able to join:

  • You are under 18 years old
  • You have a reason why having an MRI scan would not be safe for you, based on a standard MRI safety questionnaire
  • You are currently pregnant or breastfeeding
  • You have had a bacterial or viral chest/respiratory illness within the past 30 days
  • You have taken part in a different clinical drug trial within the past 30 days
  • You have any known heart rhythm problem
  • The special vest used for the MRI scan does not fit you physically
  • You are unable to hold your breath for 15 seconds
  • You may have difficulty following instructions during the scan (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Joseph Mammarappallil, M.D., Duke University

Phone: 919-681-7362

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Bastiaan Driehuys
Registry
ClinicalTrials.gov
Start date
1 January 2011
Est. completion
1 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov